Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Cranial Nerve Diseases
  • Interleukin-1beta
  • Synovitis
  • Uveitis

abstract

  • The pathogenesis of Blau syndrome may be mediated by IL-1, and canakinumab may be useful when this disorder is unresponsive to more conventional treatments.

publication date

  • February 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3684148

Digital Object Identifier (DOI)

  • 10.1002/art.37776

PubMed ID

  • 23124805

Additional Document Info

start page

  • 513

end page

  • 8

volume

  • 65

number

  • 2